DeepMed Research

Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

Maintenance Dovitinib for Colorectal and Pancreas Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer
Pancreas Cancer

Interventions: Drug: Dovitinib

First Posted Date: 2013-06-28

Last Posted Date: 2016-07-19

Lead Sponsor: Georgetown University

Target Recruit Count: 9

Registration Number: NCT01888965

Locations: 🇺🇸
Georgetown University- Lombardi Cancer Center, Washington, District of Columbia, United States

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Colorectal Cancer
Head and Neck Cancer

Interventions: Drug: Nilotinib + Cetuximab

First Posted Date: 2013-06-06

Last Posted Date: 2019-02-08

Lead Sponsor: Georgetown University

Target Recruit Count: 15

Registration Number: NCT01871311

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

Conditions: Cholestasis of Parenteral Nutrition

First Posted Date: 2013-05-24

Last Posted Date: 2019-05-07

Lead Sponsor: Georgetown University

Registration Number: NCT01861834

Locations: 🇺🇸
MedStar Georgetown Transplant Institute, Washington, District of Columbia, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

Impact Evaluation of Community-Based Health Programs in Rwanda

Not Applicable

Completed

Conditions: Diarrhea
Malaria

Interventions: Behavioral: Minimum Intervention
Behavioral: Classic Intervention

First Posted Date: 2013-04-22

Last Posted Date: 2017-07-14

Lead Sponsor: Georgetown University

Target Recruit Count: 8718

Registration Number: NCT01836731

Locations: 🇷🇼
IPA Rwanda District Office, Kamembe, Rusizi District, Rwanda
🇷🇼
Innovations for Poverty Action, Kigali, Rwanda

Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids

Phase 2

Terminated

Conditions: Chronic Pain

Interventions: Drug: Placebo
Drug: Pregabalin

First Posted Date: 2013-04-01

Last Posted Date: 2017-02-09

Lead Sponsor: Georgetown University

Target Recruit Count: 4

Registration Number: NCT01821430

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Vemurafenib
Drug: Cobimetinib

First Posted Date: 2013-03-18

Last Posted Date: 2019-02-26

Lead Sponsor: Georgetown University

Target Recruit Count: 5

Registration Number: NCT01813214

Locations: 🇺🇸
Georgetown Lombardi Comprehsnive Cancer Center, Washington, District of Columbia, United States
🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Enhanced Consent for Symptom Provocation Research

Not Applicable

Terminated

Conditions: Trauma

Interventions: Behavioral: Enhanced consent procedure
Behavioral: Consent as Usual

First Posted Date: 2013-03-13

Last Posted Date: 2018-01-24

Lead Sponsor: Georgetown University

Target Recruit Count: 12

Registration Number: NCT01809899

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Phase 4

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Etanercept
Drug: Infliximab
Drug: Adalimumab

First Posted Date: 2013-02-15

Last Posted Date: 2024-02-28

Lead Sponsor: Georgetown University

Target Recruit Count: 290

Registration Number: NCT01793519

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Not Applicable

Terminated

Conditions: Head and Neck Squamous Cell Cancer

Interventions: Drug: Cisplatin
Drug: cetuximab
Radiation: Radiation

First Posted Date: 2013-02-13

Last Posted Date: 2014-10-02

Lead Sponsor: Georgetown University

Target Recruit Count: 2

Registration Number: NCT01790516

Locations: 🇺🇸
Georgetown Lombardi Comprhensive Cancer Center, Washington, District of Columbia, United States

A Study of the Effects of PEITC on Oral Cells With Mutant p53

Phase 1

Completed

Conditions: Oral Cancer

Interventions: Dietary Supplement: Watercress Juice

First Posted Date: 2013-02-13

Last Posted Date: 2015-03-23

Lead Sponsor: Georgetown University

Target Recruit Count: 55

Registration Number: NCT01790204

Locations: 🇺🇸
Georgetown Clinical Research Unit, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy